Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P930036/S026

ADVIA Centaur AFP and Atellica IM Alpha Fetoprotein (AFP)

Siemens Healthcare Diagnostics, Inc. · Decision date May 11, 2026

FDA DECISIONP930036/S026

What did the FDA approve?

FDA records P930036/S026 as a supplement to PMA P930036, with the supplement type “Real-Time Process”. The recorded decision is approval, dated May 11, 2026.

FDA approval order statement

a change that will implement control system (medical decision pools and tiered standards) and a traceability (update to 22/216, 2nd WHO International Standard) change.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Immunology
Decision date
May 11, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P930036/S026
Regulatory pathway
PMA supplement
Product code
LOK
Decision code
APPR
Decision date
May 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS.

Product code
LOK
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P930036/S026 received

    Application receipt date recorded by FDA.

  2. P930036/S026 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P930036. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code LOK

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.PMA supplementSep 22, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 20, 2026FDA
IMMULITE 2000 AFPP010007/S026
Siemens Healthcare Diagnostics, Inc.PMA supplementJul 27, 2026FDA
ABBOTT LABORATORIESPMA supplementMay 11, 2026FDA
IMMULITE 2000 AFPP010007/S025
Siemens Healthcare Diagnostics, Inc.PMA supplementApr 21, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Healthcare Diagnostics, Inc.

Headquarters
Not reported
FDA applicant address
333 Coney St., East Walpole, MA, 02032

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records